about
Cost-utility analysis to control Campylobacter on chicken meat: dealing with data limitations.Measuring underreporting and under-ascertainment in infectious disease datasets: a comparison of methods.New methodology for estimating the burden of infectious diseases in EuropeEffects of an ageing population and the replacement of immune birth cohorts on the burden of hepatitis A in the Netherlands.The pathogen- and incidence-based DALY approach: an appropriate [corrected] methodology for estimating the burden of infectious diseases.Rationale and design of the costs, health status and outcomes in community-acquired pneumonia (CHO-CAP) study in elderly persons hospitalized with CAPUse of DALYs in economic analyses on interventions for infectious diseases: a systematic reviewDesign of the PROUD study: PCR faeces testing in outpatients with diarrhoea.Disease Burden of 32 Infectious Diseases in the Netherlands, 2007-2011.Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-UpEndoscopic mucosal resection (EMR) versus endoscopic submucosal dissection (ESD) for resection of large distal non-pedunculated colorectal adenomas (MATILDA-trial): rationale and design of a multicenter randomized clinical trial.Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational studyThe impact of community-acquired pneumonia on the health-related quality-of-life in elderlyCost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands.Smoking is Associated With Extra-intestinal Manifestations in Inflammatory Bowel Disease.The Economic Impact of the Introduction of Biosimilars in Inflammatory Bowel Disease.The economic burden of a Salmonella Thompson outbreak caused by smoked salmon in the Netherlands, 2012-2013.Effect of aging on healthcare costs of inflammatory bowel disease: a glimpse into the future.Integrated approaches for the public health prioritization of foodborne and zoonotic pathogens.Self-reported Health Care Utilization of Patients with Inflammatory Bowel Disease Correlates Perfectly with Medical Records.Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFα Therapy.Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis.Cost-of-illness and disease burden of food-related pathogens in the Netherlands, 2011.The disease burden of hepatitis B, influenza, measles and salmonellosis in Germany: first results of the burden of communicable diseases in Europe study.Comment on 'Cost effectiveness of collagen crosslinking for progressive keratoconus in the UK NHS'.Erratum to: Hospitalization costs for community-acquired pneumonia in Dutch elderly: an observational study.Disease burden of foodborne pathogens in the Netherlands, 2009.Towards an integrated approach in supporting microbiological food safety decisions.Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?High impact of migration on the prevalence of chronic hepatitis B in the Netherlands.Risk factors of work disability in patients with inflammatory bowel disease--a Dutch nationwide web-based survey: work disability in inflammatory bowel disease.Smoking is Associated with Higher Disease-related Costs and Lower Health-related Quality of Life in Inflammatory Bowel Disease.Assessing Self-reported Medication Adherence in Inflammatory Bowel Disease: A Comparison of Tools.Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study.Model based analysis of hepatitis B vaccination strategies in the Netherlands.Correction: The Pathogen- and Incidence-Based DALY Approach: An Appropriated Methodology for Estimating the Burden of Infectious Diseases.Response to comment on article by Jit et al. “The cost effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe”An update to “The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe”The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe
P50
Q31134164-4B7E9270-1882-40C2-96DE-4907D7AB81DCQ33588413-B54BDBC2-E963-4B58-97F1-E097C114F6E1Q34243524-2E1CB14E-B2B8-429F-A15E-F6D8A877C313Q34622848-1428C170-AE4A-4376-B1B0-AC352BF89D59Q35053236-395053C6-9565-4484-B28A-8682D82BABDCQ35071890-09C596D8-A4F7-4343-ACD9-5E8748682D88Q35686520-DB40C176-BDB0-4900-8336-3FF154FA85A8Q35910370-D03F6B6B-D844-4BE6-870C-3A52FD4AD2D1Q35994858-343EC05C-8064-4617-82A0-58326B9F8743Q35995603-7346EE55-99E1-4B1A-90B0-DB0540B2D1C0Q36031309-DF13D2AE-2C71-4441-970E-A5AA44DD31B4Q36121879-A323F0BB-6ADB-4CE5-8C59-F061720F8D57Q36307771-EFE500F4-691F-47B6-870F-14AF59C48BC0Q36571135-217F808C-A2C7-4059-AA47-5786B693199AQ37098416-D881F391-FF9A-4F4E-BC3D-C36178A4F8B1Q38826838-F93E5185-8BF1-4F20-9562-D15BF9110055Q39193922-271AFB48-4EF6-4759-879A-CFA74D0CBBACQ39252060-CD4B672A-1465-4A92-A685-A947D4983748Q39945929-AF1527A4-6CCC-4843-93A5-3A51D3EA8F09Q40032358-68B51039-4118-4B58-B1D3-20D6E39563CDQ40646446-E716EAD0-F481-4FDF-A48C-F10D04B3035CQ40932197-8CD27F25-5F5D-489C-A64B-473E3A25D3DBQ41589035-EEB29FCA-8400-4ED9-A881-87D6496B53ECQ42230427-61CA7E0F-6103-4A48-B611-447198F79424Q42355392-64C03884-B09C-4644-8F17-FC9398A0B3A9Q42363418-123B7030-4BFB-4E57-8C59-BFA123BB29C1Q43015262-F1FDCDEB-F215-4058-8DA0-A435CAFD3BA2Q43222495-0DD67863-58D5-4D25-9D38-38212A5BF09AQ44046271-FD34A8E9-117E-4C5D-AA00-7A920E555FF3Q44275068-8C5C7DB7-ACDC-441F-82EC-2A31F5276246Q44986929-53C5F542-6CCD-44F6-8EE8-0125D361903AQ46010903-B5FB6AA9-E532-40F9-910E-315046EE5F89Q47656552-A3061FD7-4177-4247-9A28-CABC54192F85Q47684103-A335A901-7466-4D35-8EB4-6BCF302E96C8Q50898166-B8436F13-4BF4-4951-A41C-CCFA8778396DQ51857756-B3677F08-E032-40FE-9837-8AD80E3FC962Q55423415-137CCF53-DEF1-446D-9656-971EDC21C1ADQ57515331-3BC9536E-CBFA-421A-B71C-75C20950CF58Q57515334-F315A381-1C96-416A-9CFA-42A80418FDA9Q57515347-B9679E01-D8B3-4569-9503-02A5826A6D78
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marie-Josée J Mangen
@ast
Marie-Josée J Mangen
@en
Marie-Josée J Mangen
@es
Marie-Josée J Mangen
@fr
Marie-Josée J Mangen
@nl
Marie-Josée J Mangen
@sl
type
label
Marie-Josée J Mangen
@ast
Marie-Josée J Mangen
@en
Marie-Josée J Mangen
@es
Marie-Josée J Mangen
@fr
Marie-Josée J Mangen
@nl
Marie-Josée J Mangen
@sl
prefLabel
Marie-Josée J Mangen
@ast
Marie-Josée J Mangen
@en
Marie-Josée J Mangen
@es
Marie-Josée J Mangen
@fr
Marie-Josée J Mangen
@nl
Marie-Josée J Mangen
@sl
P106
P1153
6602698300
P21
P31
P496
0000-0001-8914-2045